Navigation Links
FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
Date:7/1/2011

s from these highly preventable surgical complications."

About XARELTO® (rivaroxaban tablets)

XARELTO® is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in people undergoing knee or hip replacement surgery. XARELTO® belongs to a group of medicines called anticoagulants. It works by blocking the blood clotting Factor Xa and thereby reduces the tendency of the blood to form clots. XARELTO® is the third New Drug Application the U.S. FDA has approved from the Janssen Pharmaceutical Companies this year.

Additionally, XARELTO® is being evaluated for the prevention and treatment of a broad range of disorders in which blood clotting plays a major role. The extensive program of clinical trials evaluating rivaroxaban makes the compound the most studied oral, Factor Xa inhibitor in the world today. By the time of its completion, more than 65,000 patients will have participated in the rivaroxaban clinical development program. Rivaroxaban is being developed jointly by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare.

Important Safety Information

WHAT IS XARELTO®?

XARELTO® (rivaroxaban tablets) is a prescription medicine used to help prevent blood clots from forming in patients after hip or knee replacement surgery.

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO®?

  • You should take XARELTO® exactly as directed by your doctor
  • Do not skip a dose or stop taking XARELTO® unless you are advised to do so by your doctor. Stopping may increase your risk of a blood clot
  • If a dose is missed, take XARELTO® as soon as possible and continue on the following day, taking XARELTO® as directed by your doctor. Do not take two doses at the same time
  • XARELTO® can cause b
    '/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
2. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
3. FDA Approves Nulojix for Kidney Transplant Patients
4. FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
5. FDA Approves First Ceramic-on-Metal Total Hip Replacement System
6. FDA Approves Redesigned Labels for Some Merck Drugs
7. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
8. FDA Approves Marketing of RMS Subcutaneous Needle Sets
9. FDA Approves Injectable Gel to Treat Fecal Incontinence
10. FDA approves Incivek for hepatitis C
11. FDA Approves Sutent for Rare Type of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015  Ardelyx, Inc. (NASDAQ: ARDX ... and metabolic diseases, today announced that the Company will ... from 8:00 a.m.- 1:00 pm EDT in ... Ardelyx senior management team will present an overview of ... which has completed Phase 2b clinical trials for the ...
(Date:6/30/2015)... JERUSALEM , June 30, 2015 ... http://www.oramed.com ), a clinical-stage pharmaceutical Company focused on the ... the first patient has been screened in the Company,s ...  This U.S. based study will be performed under the ... the U.S. Food and Drug Administration (FDA). ...
(Date:6/30/2015)... YORK , June 30, 2015 /PRNewswire/ – Small ... had an agreement to supply custom Arrayit blood card ... human DNA vault on earth. Vivos offers an impervious, ... virtually every man, woman and child on Earth, a ... their DNA. Arrayit blood cards allow the rapid collection, ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3Small Cap IR - Empowering the Age of Genetic Enlightenment 2
... SOUTH SAN FRANCISCO, Calif., May 6 Exelixis,Inc. ... for the first quarter,ended March 31, 2008., ... were $27.9 million,compared to $28.1 million for the ... consistent with 2007, but reflect the completion of,revenue ...
... DIEGO, May 6 TriLink BioTechnologies (TriLink), ... has been awarded a,Phase II Small Business ... continue its investigation of modified dNTPs to ... studies demonstrated that TriLink,s,unique dNTP modifications enhanced ...
Cached Medicine Technology:Exelixis Announces First Quarter 2008 Financial Results 2Exelixis Announces First Quarter 2008 Financial Results 3Exelixis Announces First Quarter 2008 Financial Results 4Exelixis Announces First Quarter 2008 Financial Results 5Exelixis Announces First Quarter 2008 Financial Results 6TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project 2
(Date:7/1/2015)... Salt Lake City, UT (PRWEB) , ... July ... ... opportunity to compare the different philosophies and approaches to case management, placement, sober ... also have different training and approaches to working with and transporting clients with ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... Georgia and the Florida Panhandle, the regional southeast Alabama community health system ... and clinical communications workflow solution provider. TelmedIQ, a burgeoning leader in secure ...
(Date:7/1/2015)... FL (PRWEB) , ... July 01, 2015 , ... Nutritional ... range of nutritional and beauty products, recently attended the 2015 ECRM Diet, Vitamin & ... connections in the retail industry. The ECRM trade show allows companies the ...
(Date:7/1/2015)... ... 2015 , ... Foot and Ankle Specialists of the Mid-Atlantic, LLC (FASMA) ... annual Howard County Family Wellness Day event at Centennial Park on June 7, 2015. ... for children, free workout demonstrations, and more. Drs. Becker and Friske educated attendees ...
(Date:7/1/2015)... ... 2015 , ... Recent research has revealed that most adults lack confidence in ... to professionals. Starting the last Monday of June, Whiter Image Dental will ... discount on the customer’s first popular In-Office 2 Patient Kit. , ...
Breaking Medicine News(10 mins):Health News:All Kinds of Therapy – Announces New Partnership Feature, Therapeutic Experts 2Health News:Southeast Alabama Community Health System Chooses TelmedIQ to Meet Secure Text Messaging Challenges for Healthcare 2Health News:NPI Meets With Top Retail Figures at ECRM Conference 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Promotes Healthy Living 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Promotes Healthy Living 3Health News:Whiter Image Dental Offers New Customers Half-Off Teeth Whitening Kit 2
... study describes a new agent, called "Zorro-LNA," which has ... In the study, researchers from the Karolinska// Institute in ... with both strands of a gene’s DNA simultaneously, effectively ... clinical implications for virtually every human condition caused by ...
... that patients suffering dementia lead a troubled existence due to ... lives. An// estimated 700,000 such patients live in The United ... is the worst that can happen to such patients; lack ... can plunge them into deeper despair. ,The study, ...
... ill young children dying in intensive care after being admitted to ... end of the 1990s,// reveals a study in the Journal of ... one large children’s hospital, to find out where children had died, ... spanned seven years from 1997 to 2004 and included all age ...
... is giving to a serious health crisis in Canada, many fear.// ... ago, about five million Canadians, or 17 per cent of the ... doctorless people, nearly two million of them, or 38 per cent, ... but have failed. ,Not having a family physician makes ...
... Loss of memory in people suffering from neuro-degenerative diseases, ... drugs that trigger the natural "rewiring" of brain// cells, ... in Cambridge, Massachusetts, and colleagues used mice that were ... an antibiotic. Previous studies have suggested that p25 is ...
... representatives from 150 nations gathered in Bangkok Monday for ... carbon emissions to slow global warming. ,"The ... of Thailand's ministry of natural resources and environment, in ... Change (IPCC). ,"Global warming has increasingly ...
Cached Medicine News:Health News:New Agent to Fight Genetic Disorders Found 2Health News:Dementia – Worse With a Dull Life. Keep Busy, and Active to Improve Memory, Study Recommend 2Health News:Significant Rise in Proportion of Chronically Ill Children Dying in Intensive Care 2Health News:Canadians Despair for Family Doctors 2
... Level 1 enables hospitals ... patient monitors to a ... Our temperature monitoring disposale ... are superior in their ...
... The pause of a heartbeat. The bodys ... rhythmic breathing. These vital signs are yours ... DeRoyals line of Temperature Monitoring products helps ... information needed to provide the most comfortable ...
... a heartbeat. The bodys warmth beneath drapes. ... vital signs are yours to guard, measure, ... Temperature Monitoring products helps you do your ... provide the most comfortable and precise management ...
... The bodys warmth beneath drapes. The life-giving ... are yours to guard, measure, stabilize and ... products helps you do your job, giving ... most comfortable and precise management of your ...
Medicine Products: